Diana Brainard
Chief Executive Officer at ALLOVIR, INC.
Net worth: 669 395 $ as of 2024-04-29
Diana Brainard active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALLOVIR, INC. | Director/Board Member | 2020-06-30 | - |
| Chief Executive Officer | 2021-05-16 | - | |
| Independent Dir/Board Member | 2019-03-31 | - | |
| NEKTAR THERAPEUTICS | Director/Board Member | 2021-11-10 | - |
| Independent Dir/Board Member | 2021-11-10 | - | |
Affinia Therapeutics, Inc.
 Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Director/Board Member | 2022-03-07 | - |
| Independent Dir/Board Member | 2022-03-07 | - | |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | - | - |
Career history of Diana Brainard
Former positions of Diana Brainard
| Companies | Position | Start | End |
|---|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 2014-12-31 | 2020-12-31 |
Training of Diana Brainard
| Brown University | Undergraduate Degree |
| Tulane University School of Medicine | Doctorate Degree |
Statistics
International
| United States | 8 |
Operational
| Director/Board Member | 3 |
| Independent Dir/Board Member | 3 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 5 |
| Consumer Services | 3 |
| Finance | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| Private companies | 2 |
|---|---|
Affinia Therapeutics, Inc.
Affinia Therapeutics, Inc. BiotechnologyHealth Technology Affinia Therapeutics, Inc. is a preclinical stage company, which engages in the research and development of gene therapy. It offers Affinia Rationally-designed Therapies (ART) platform, which develops novel therapies, focusing on the key components of a gene therapy: capsids, which are the outer shells of a virus used to package the genetic code to treat a disease; promoters, which control how the cells read the genetic code that is delivered; and manufacturing approaches, which determine the quality and cost of potential medicines. The company was founded by Luk Vandenberghe, Botond Roska, and Aaron Tward in 2019 and is headquartered in Waltham, MA. | Health Technology |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
- Stock Market
- Insiders
- Diana Brainard
- Experience
